Haima Therapeutics LLC
Cell-inspired therapies for bleeding and blood disorders.
Cleveland, United States · Founded 2018 · $4.0M raised
- Headquarters
- Cleveland, Ohio
- Employees
- 1–10
- Founded
- 2018
- Business Model
- B2G
- Website
- haimatherapeutics.com
- Total Funding
- $4.0M
- Last Round
- $4.0M GrantSep 2025
- Rounds
- 2
About
Haima Therapeutics is a pre-clinical stage biopharma company developing cell-inspired therapies for bleeding and blood-related diseases. Its lead technology, SynthoPlate, is a fully-synthetic nanoparticle-based hemostatic agent that mimics platelet function to control hemorrhagic bleeding after trauma, surgery, or in rare bleeding disorders. The company has received SBIR funding from DARPA, NIH, and NSF to advance SynthoPlate toward first-in-human clinical trials.
Summary
Haima Therapeutics LLC is a Biotech company based in Cleveland, United States, founded in 2018. It has raised $4.0M in total across 2 rounds, most recently a $4.0M Grant round in Sep 2025. Investors include Defense Advanced Research Projects Agency and National Institutes of Health.
Tech & App Stack
1 technologies & apps tracked
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Sep 2025
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Biopharmaceutical services company
Specialty pharmaceutical company